Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) calls for the ordinary general meeting to be held on Tuesday 25 March 2014 at 3 pm (CET) at the company’s address, Skelstedet 16, 2950 Vedbaek, Denmark. A copy of the notice with the complete proposals is attached hereto and can also be seen at www.exiqon.com.
Additional information
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
Exiqon operates in two business segments: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of research products for microRNA analysis. Exiqon Diagnostics develops novel molecular diagnostic tests for stratification of patients, for clinical trials, early detection of diseases and to help physicians make treatment decisions based on RNA profiling. Exiqon is listed on NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.
